𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Development of a membrane array-based multimarker assay for detection of circulating cancer cells in patients with non-small cell lung cancer

✍ Scribed by Chau-Chyun Sheu; Ya-Ping Yu; Jong-Rung Tsai; Mei-Yin Chang; Shiu-Ru Lin; Jhi-Jhu Hwang; Inn-Wen Chong

Publisher
John Wiley and Sons
Year
2006
Tongue
French
Weight
373 KB
Volume
119
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Combination of multiple mRNA markers has been largely investigated for detection of circulating cancer cells. However, current PCR‐based methods are relatively expensive and time consuming. The aim of this study was to develop a membrane array‐based multimarker assay for detection of circulating cancer cells in nonsmall cell lung cancer (NSCLC) patients. At first, we selected 22 candidate genes by means of suppression subtractive hybridization and Northern blot analysis. The diagnostic value of each candidate gene was then preliminarily evaluated in 50 pairs of blood samples by membrane array method. Accordingly, 17 genes with area under the ROC curve (AUC) ≥ 0.8 were selected as target genes to reconstruct the diagnostic membrane array, which was then used to test peripheral blood samples from 100 NSCLC patients and 147 control subjects. ROC curve analysis demonstrated that the optimal threshold number of overexpressed markers on membrane array for discrimination between NSCLC patients and control subjects was 12. As a result, the diagnostic membrane array could detect circulating cancer cells in 90 (90%) of 100 NSCLC patients and in 14 (9.5%) of 147 control subjects (including 6 of 100 normal persons, 3 of 20 breast cancer patients, 3 of 15 colorectal cancer patients and 2 of 12 gastric cancer patients). Moreover, the detection rate was significantly correlated with NSCLC patients' metastatic status and overall stage (p = 0.028 and 0.014, respectively). These results suggested that our blood‐based membrane array assay for molecular detection of circulating lung cancer cells has great potential for clinical applications. © 2006 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Development of a high-throughput membran
Development of a high-throughput membrane-array method for molecular diagnosis of circulating tumor cells in patients with gastric cancers
✍ Chan-Hang Wu; Shiu-Ru Lin; Fang-Jung Yu; Deng-Chyang Wu; Yong-Sang Pan; Jan-Sing 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 374 KB 👁 1 views

## Abstract Recently several noninvasive methods have been employed to detect circulating tumor cells (CTCs) in cancer patients. In this study, we have developed a highly sensitive, high‐throughput colorimetric membrane‐array method that was designed to detect a panel of mRNA markers including huma

Potential of magnetization transfer MRI
Potential of magnetization transfer MRI for target volume definition in patients with non-small-cell lung cancer
✍ Johannes F.T. Arnold; Markus Kotas; Robert W. Pyzalski; Eberhard D. Pracht; Mich 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 461 KB 👁 1 views

## Abstract ## Purpose To develop a magnetization transfer (MT) module in conjunction with a single‐shot MRI readout technique and to investigate the MT phenomenon in non‐small‐cell lung cancer (NSCLC) as an adjunct for radiation therapy planning. ## Materials and Methods A total of 10 patients

Detection of epidermal growth factor rec
Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer
✍ Chen He; Ming Liu; Chengzhi Zhou; Jiexia Zhang; Ming Ouyang; Nanshan Zhong; Jun 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 260 KB 👁 2 views

## Abstract The high frequency of epidermal growth factor receptor (__EGFR__) mutations in tyrosine kinase inhibitor‐responsive non‐small‐cell lung cancer (NSCLC) cases is now well established, highlighting the predictive value of activating __EGFR__ mutations in guiding the clinical use of __EGFR_

CD80 expression in an HLA-A2-positive hu
CD80 expression in an HLA-A2-positive human non-small cell lung cancer cell line enhances tumor-specific cytotoxicity of HLA-A2-positive T cells derived from a normal donor and a patient with non-small cell lung cancer
✍ Dale L. Bixby; John R. Yannelli 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 185 KB 👁 2 views

To generate non-small cell lung cancer (NSCLC)-reactive lymphocytes, we transfected an HLA-A2-expressing human NSCLC line (1355) with the cDNA encoding the lymphocyte co-stimulatory molecule CD80. Following selection in G418, 1355.7 demonstrated stable cell-surface expression of CD80. Allogeneic mix

Overexpression of S100A2 protein as a pr
Overexpression of S100A2 protein as a prognostic marker for patients with stage I non small cell lung cancer
✍ Huijun Wang; Zhengdong Zhang; Ruiyun Li; K. Kian Ang; Huazhong Zhang; Nancy P. C 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 313 KB 👁 2 views

## Abstract S100A2, a calcium‐binding protein, recently became of major interest because of its differential expression during transformation and metastasis in various tumors. The purpose of this study was to investigate the prognostic significance of S100A2 expression in the early‐stage non small